Evolving role of positron emission tomography in breast cancer imaging

18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has been used for detection, staging, and response monitoring in breast cancer patients. Although studies have proven its accuracy in detection of the primary tumor and axillary staging, its most important current clinical application is...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in nuclear medicine 2005-04, Vol.35 (2), p.84-99
Main Authors: Eubank, William B., Mankoff, David A.
Format: Article
Language:English
Subjects:
Breast Neoplasms - diagnostic imaging
Breast Neoplasms - therapy
Female
Fluorodeoxyglucose F18
Humans
Lymphatic Metastasis
Neoplasm Recurrence, Local - diagnostic imaging
Neoplasm Recurrence, Local - prevention & control
Positron-Emission Tomography - methods
Positron-Emission Tomography - trends
Prognosis
Radiopharmaceuticals
Risk Assessment - methods
Risk Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has been used for detection, staging, and response monitoring in breast cancer patients. Although studies have proven its accuracy in detection of the primary tumor and axillary staging, its most important current clinical application is in detection and defining the extent of recurrent or metastatic breast cancer and for monitoring response to therapy. PET is complementary to conventional methods of staging in that it provides better sensitivity in detecting nodal and lytic bone metastases; however, it should not be considered a substitute for conventional staging studies, including computed tomography and bone scintigraphy. FDG uptake in the primary tumor carries prognostic information, but the underlying biochemical mechanisms responsible for enhanced glucose metabolism have not been completely elucidated. Future work using other PET tracers besides FDG will undoubtedly help our understanding of tumor biology and help tailor therapy to individual patient by improving our ability to quantify the therapeutic target, identify drug resistance factors, and measure and predict early response.
ISSN:0001-2998
1558-4623
DOI:10.1053/j.semnuclmed.2004.11.001